# Buzzkill Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/buzzkill-labs

- Industry: Medical Devices & Equipment
- Headquarters: Livermore, US
- Website: www.buzzkilllabs.com
- Total disclosed funding: $4.4M
- Latest round: Series A (Apr 19, 2023)
- Investors on record: 1

## About

Established in 2018 and based in California, US, Buzzkill Labs, Inc. operates as a provider of rapid saliva tests for the detection of psychoactive compounds to test for cannabis use. In May 2023, Buzzkill Labs, Inc. raised Series A funding from new investor Poseidon Asset Management, with participation from other unspecified investors. As of May 2023, the company is being led by CEO Jeff Heimburger and CTO George Farquar.



The firm employs its proprietary technology that detects the use of cannabis by employees in the workplace by testing the oral samples of workers (saliva) for the presence of psychoactive compounds such as Delta-9-tetrahydrocannabinol. 



The company intends to use the May 2023 funding to expand its market reach and product development.

## Funding rounds

- Series A, Apr 19, 2023, $4.4M — Poseidon Asset Management

## Investors

- Poseidon Asset Management (https://capitalatlas.ai/funds/poseidon-asset-management) — Series A